To the best of our knowledge, there has been no report on the incidence of EGFR mutations in lung adenocarcinomas from Iran, and this study is the first one performed in Iran from a molecular approach on the frequency of EGFR mutations and their relation to the clinicopathological characteristics of lung adenocarcinomas. The gene discussed is EGFR; the disease is lung adenocarcinoma.